l General Information |
Product Name | Droxidopa |
General description | Droxidopa is a precursor of noradrenaline that is used in the treatment of parkinsonism. |
Synonym | L-threo 3,4-Dihydroxyphenylserine; L-DOPS |
Purity | ≥98%(HPLC) | CAS Number | 23651-95-8 |
Formula | C9H11NO5 | Molecular Weight | 213.19 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Yellow white solid |
Solubility(25℃) | DMSO | Insoluble |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope through the induction of tachycardia (increased heart rate) and hypertension. |
Application | Antiparkinson Agents |
l Packaging & Storage |
Packaging | 250mg; 1g |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
